Zealand Pharma — Marts 2022

[Svingtraderen]

er der nu

[exitnu]

Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

Company announcement – No. 7 / 2022Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for...

GlobeNewswire News Room (www.globenewswire.com)

[Svingtraderen]

fab - tak

[exitnu]

Financial results for the full year 2021
• Revenue of DKK 292.6 million / USD 44.6 million (2020: DKK 353.3 million / USD 54.2 million).
• Net operating expenses of DKK 1,224.7 million / USD 186.7 million (2020: DKK 1,092.1 million / USD 166.9 million).
• Operating result for the year of DKK -1,052.4 million / USD -160.4 million (2020: DKK -792.4 million / USD -121.4 million).
• Cash including marketable securities amounted to DKK 1,428.1 million / USD 217.7 million at year-end (2020: DKK 1,257.

[exitnu]

Financial guidance
In 2022, Zealand Pharma expects net product revenue from the sales of its commercial products of DKK 235.0 million +/-10% compared to 2021 of DKK 184.0 million.

[exitnu]

In 2022, Zealand Pharma expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand Pharma does not intend to provide guidance on such revenue.

[exitnu]

Net operating expenses in 2022 are expected to be DKK 1,200.0 million +/-10% compared to 2021 of DKK 1,224.7 million.

[exitnu]

Zegalogue net revenue for FY 2021 was DKK 5.5 million / USD $0.8 million.

[exitnu]

V-Go net revenue for the FY 2021 was DKK 178.5 million / USD $28.5 million.

[Svingtraderen]

nogen holdning bagefter?

[exitnu]

Kort og godt: på sporet. Haltende Zegalogue salg, godt V-Go salg. De guider konservativt. Ingen overraskelser i pipelinen

[Svingtraderen]

tak

[exitnu]

Selvtak. Og selvfølgelig mange triggers resten af 2022.

[exitnu]

Conference call March 10, 2022, at 4:00 PM CET (10:00 AM EDT).

A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/mmc/p/7daetm5k

[exitnu]

Biotekselskabet Zealand Pharma venter i 2022 omkostninger i niveauet 1200 mio. kr. og et salg af kommercielle produkter for 235 mio. kr.
Det fremgår af selskabets årsregnskab for 2021.

I 2021 realiserede Zealand Pharma omkostninger på 1224,7 mio. kr. og et salg af kommercielle produkter for 184,0 mio. kr.

.\˙ MarketWire

[ProinvestorNEWS]

Zealand Pharma - Full Year Results for 2021 https://www.proinvestor.com/boards/101883

[lassevedel96]

I 2021 har de brugt 385 millioner DKK på salg og marketing og 261 millioner DKK på administration, hvoraf meget af dette er gået til opbygning af kommerciel infrastruktur. Er jeg den eneste der synes, at det er fuldstændig vanvittige tal, især set i lyset af det ekstremt skuffende salg på blot 5.5 millioner DKK Zegalogue?

[exitnu]

De guidede plus/minus 10 pct. og ramte minus 3.1 pct.

[lassevedel96]

Salget er endda gået ned, fra 3.1 mDKK til 2.4 mDKK. Til sammenligning solgte Xeris Pharma deres Gvoke pen for 23 mDKK samlet i deres to første fuld
e kommercielle kvartaler (og det var ligeledes under corona)

[ProinvestorNEWS]

Zealand Pharma i nyt underskud - ser omkostninger på 1,2 mia kr i 2022 https://proinvestor.com/investornyt/793587/zealand-pharma-i-nyt-underskud-ser-omkostninger-pa-12-mia-kr-i-2022